Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors

The patent, which expires in 2036, covers the treatment of NT-219, the companys novel dual inhibitor of IRS 1/2 and STAT3, in combination with EGFR antibodies and inhibitors.